BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 363650)

  • 1. [Possibilities of immunotherapy in malignant melanoma].
    Lewis MG
    Hautarzt; 1978 Dec; 29(12):619-24. PubMed ID: 363650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development in the immunotherapy of malignant melanoma].
    Tritsch H
    Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune response and non-specific immunotherapy in melanoma.
    El-Domeiri AA
    Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possibilities of immunotherapy and gene therapy for malignant melanoma.
    Crowley NJ; Seigler HF
    Semin Surg Oncol; 1993; 9(3):273-8. PubMed ID: 8516616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
    Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
    Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Basis for a specific-active immunotherapy in malignant melanoma].
    Mutzner PA; Stuhlmiller GM; Seigler HF; Stumpf WE; Sar M
    Schweiz Med Wochenschr; 1981 Sep; 111(36):1322-5. PubMed ID: 7302537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological factors which influence response to immunotherapy in malignant melanoma.
    Morton D; Eilber FR; Malmgren RA; Wood WC
    Surgery; 1970 Jul; 68(1):158-63; discussion 163-4. PubMed ID: 10483463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunotherapeutic possibilities for treatment of malignant melanomas].
    Kokoschka EM
    Hautarzt; 1979 Dec; 30(12):656-61. PubMed ID: 317654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.
    Mitchell MS; Mokyr MB; Davis JM
    J Clin Invest; 1977 Jun; 59(6):1017-26. PubMed ID: 863999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in malignant melanomaa.
    Homes EC; Morton DL; Eilber FR; Golub SE; Sulit HL
    Natl Cancer Inst Monogr; 1976 Nov; 44():85-6. PubMed ID: 799763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current concepts in the management of malignant melanoma.
    Lichtenfeld JL
    Am J Med Sci; 1976; 272(2):185-95. PubMed ID: 1008080
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunotherapeutic approaches for the treatment of malignant melanoma.
    Curiel-Lewandrowski C; Atkins MB
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1553-63. PubMed ID: 11763157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
    Pullmann H; Muth M
    Z Hautkr; 1982 Feb; 57(4):294-7. PubMed ID: 7080583
    [No Abstract]   [Full Text] [Related]  

  • 16. Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides.
    Ueda Y; Shimizu K; Itoh T; Fuji N; Naito K; Shiozaki A; Yamamoto Y; Shimizu T; Iwamoto A; Tamai H; Yamagishi H
    Jpn J Clin Oncol; 2007 Feb; 37(2):140-5. PubMed ID: 17255158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current results with surgery and adjuvant chemotherapy in malignant melanoma].
    Mechl Z; Kopecný J
    Arch Geschwulstforsch; 1986; 56(5):367-71. PubMed ID: 2429631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [DTIC in malignant melanoma: a perspective (author's transl)].
    Kokoschka EM
    Wien Klin Wochenschr; 1978 Dec; 90(24):870-4. PubMed ID: 369152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress of immunotherapy in the treatment of malignant melanoma.
    Ariyan S
    Yale J Biol Med; 1975 Nov; 48(5):423-9. PubMed ID: 1108459
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
    Wood WC; Cosimi AB; Carey RW; Kaufman SD
    Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.